Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Inflammatory cytokine-reducing compounds designed at Celgene

Oct. 30, 2000

E-6060, a potential new therapy for antibody-dependent autoimmune diseases

Oct. 30, 2000

Inflammatory and autoimmune disease treatment enters phase I testing

Oct. 26, 2000

FDA grants priority review status to Genelabs' NDA for new lupus therapy

Oct. 26, 2000

Remicade recommended for approval in Europe for broader application

Oct. 26, 2000

MitoKor and UCSD receive BioSTAR grant for osteoarthritis research

Oct. 26, 2000

Phase III trial of lupus drug LJP-394 begins

Oct. 25, 2000

Celebrex introduced in major European market

Oct. 23, 2000

NO-releasing paracetamol derivative exerts both analgesic and antiinflammatory effects

Oct. 20, 2000

Dimethaid Research seeks approval for topical osteoarthritis treatment in Canada

Oct. 18, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...